Explore the efficacy and safety concerns of Molnupiravir, an oral medication developed by Merck for mild to moderate COVID-19 cases, in this comprehensive 33-minute lecture. Delve into the drug's mechanism of action, pharmacology, intended population, and potential risks. Learn about the latest developments in COVID-19 treatment as Professor Zach Murphy presents detailed information supported by scientific references. Gain valuable insights into this innovative antiviral medication and its role in combating the ongoing pandemic.
Overview
Syllabus
Lab.
Molnupiravir Introduction.
Mechanism of Action (MOA).
Molnupiravir Pharmacology.
Population Targeted.
Efficacy.
Safety Concerns.
Comment, Like, SUBSCRIBE!.
Taught by
Ninja Nerd
Related Courses
-
Clinical management of patients with COVID-19: Investigations and care for mild, moderate and severe disease
-
COVID-19 Course for Leaders, Educators, Learners and General Public
4.0 -
Long-term care facilities in the context of COVID-19
-
Management and Facilitation of a Country COVID-19 Intra-Action Review (IAR)
-
The Delta Variant - Current Evidence and Literature - COVID-19 - SARS-CoV-2 - Vaccine Efficacy
-
Antimycobacterials - Anti-TB Drugs
